I don't understand..someone please explain:
Roche paid $65 mill up front and up to $530 in milestones for exclusive rights to market Octreolin.....for Acromegaly
Atl1103 is more potent,cheaper.and safer than the major treatment drugs at present
The estimated market for Anp is $200 million per annum
And you guys are talking $5 and $10 mill license fees....lol
Atl1102 has not gone to market or interested pharmas because only a month ago they got the OK from the FDA...
Expect the same license fees as above,
ANP Price at posting:
8.5¢ Sentiment: Buy Disclosure: Held
